Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Penile nerve block tied to higher revision surgery rates after hypospadias repair

30 Sep 2020

Penile nerve blocks (PNBs), rather than caudal epidural blocks (CEBs), may lead to higher rates of revision surgery after hypospadias repair, a recent study has found.

The study included 188 paediatric patients (mean age at surgery, 21.3±23.0 months) who underwent primary distal hypospadias repair. The outcome was revision surgery, defined as reoperation for fistulae, strictures, dehiscence, or meatal stenosis. Patient records were retrieved from a database at the Queensland Children’s Hospital.

Of the participants, 60.6 percent (n=114) received a PNB, while 39.4 percent (n=74) received a CEB. Over a median follow-up of 20 months, 31 revision surgeries were performed, corresponding to a rate of 16.5 percent.

The main indications for revision surgery included urethrocutaneous fistulae (9.0 percent), meatal stenosis or strictures (4.8 percent), and glans dehiscence (2.7 percent).

Unadjusted Cox regression analysis revealed that only PNB was a significant risk factor for revision surgery (hazard ratio [HR], 2.55, 95 percent confidence interval [CI], 1.04–6.27; p=0.04). Adjusting for confounders did not attenuate this interaction, instead even increasing the magnitude of its effect (HR, 2.74, 95 percent CI, 1.09–6.92; p=0.03). This analysis used CEB as a reference.

Other potential risk factors, such as age, surgeon training, type of surgery, and American Society of Anaesthesiologist grade, were all unrelated to revision surgery risk.

The researchers, however, pointed out that randomization was not performed, and therefore the study could not account for selection bias. In addition, the findings only apply to distal hypospadias repair, and complications may occur for midshaft and proximal repairs, as well as at older ages.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.